Presentation Scheduled for 11:30 am Eastern Time on August 8th
NASDAQ, TSX: NVCN
VANCOUVER, Aug. 5, 2019 /PRNewswire/ - Neovasc, Inc.
("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies and in the development of minimally
invasive devices for the treatment of refractory angina, today
announced that Fred Colen, Chief
Executive Officer, will present a corporate overview at the
Canaccord Genuity 39th Annual Growth Conference, being
held August 7-8, 2019 in Boston, Massachusetts.
Presentation Details:
|
Date:
|
Thursday, August
8
|
|
Time:
|
11:30am Eastern
Time
|
|
Webcast:
|
http://wsw.com/webcast/canaccord35/nvcn/
|
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for
the rapidly growing cardiovascular marketplace. Its products
include the Neovasc Reducer™ (the "Reducer"), for the treatment of
refractory angina, which is not currently commercially available in
the United States and has been
commercially available in Europe
since 2015, and the Tiara™, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United
States, Canada and
Europe. For more information,
visit: www.neovasc.com.
View original
content:http://www.prnewswire.com/news-releases/neovasc-to-attend-canaccord-genuity-39th-annual-growth-conference-300895468.html
SOURCE Neovasc Inc.